Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387490 | 0.86 | KDM1A (0.37) | KDM1AHTR2AMAOAMAOB | |
| SCHEMBL2387520 | 0.82 | OPRD1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL2386806 | 0.82 | KDM1A (0.39) | KDM1AHTR2ASIGMAR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL2386807 | 0.82 | KDM1A (0.39) | KDM1AHTR2ASIGMAR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL2386805 | 0.82 | KDM1A (0.39) | KDM1AHTR2ASIGMAR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL2387901 | 0.82 | KDM1A (0.39) | KDM1AHTR2ASIGMAR1MAOAMAOB | |
| SCHEMBL2385308 | 0.80 | KDM1A (0.44) | KDM1ASIGMAR1 | |
| SCHEMBL150397 | 0.77 | SIGMAR1 (0.39) | KDM1AHTR2ASIGMAR1 | |
| SCHEMBL29371697 | 0.77 | SIGMAR1 (0.39) | KDM1AHTR2ASIGMAR1 | |
| SCHEMBL2390411 | 0.76 | HTR2A (0.44) | KDM1AHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | claimed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | claimed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | claimed |
| CN-101489984-A | Aminoindan derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-07-22 | — | — | CN | claimed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | claimed |
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| CN-101489984-B | Aminoindan derivative or salt thereof | ASTELLAS PHARMA INC | 2013-04-03 | — | — | CN | disclosed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| CN-101489984-A | Aminoindan derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | GRIN3A, OPRL1, GRIN2A | KDM1A 3209/4885HTR2A 86/4885SIGMAR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.